Interaction of xenobiotics with myocardial signal transduction pathways

Russell B Melchert1, Jacob Joseph, Richard H Kennedy

  • 1University of Arkansas for Medical Sciences, Department of Pharmaceutical Sciences, Little Rock, AR 72205, USA. RussellB@uams.edu

Insights

Xenobiotics, or foreign compounds, can disrupt cardiac myocyte growth and death signaling pathways. Understanding these interactions is crucial for identifying new research directions in cardiotoxicity.

Area of Science:

  • Cardiovascular Toxicology
  • Molecular Cardiology
  • Pharmacology

Background:

  • While cardiac ion channel function alterations by toxicants are well-studied, the impact of xenobiotics on cardiac myocyte growth and death signaling remains largely unknown.
  • Cardiac myocyte growth involves pathways like MAPKs, JAK-STATs, and calcium signaling, while death pathways include caspases and p53.

Purpose of the Study:

  • To review current knowledge on how xenobiotics interact with myocardial signal transduction pathways.
  • To highlight areas for future research in xenobiotic-induced cardiotoxicity.

Main Methods:

  • Literature review of studies investigating xenobiotic effects on cardiac signaling.
  • Analysis of known signaling pathways involved in cardiac myocyte growth and apoptosis.

Main Results:

  • Several cardiotoxicants are known to affect cardiac myocyte signaling pathways, but the clinical significance is unclear.
  • Xenobiotics can also impact cardiac signaling indirectly by altering the cardiac interstitium or extracellular matrix.

Conclusions:

  • There is significant crosstalk between cardiac growth and death pathways, suggesting a delicate balance that can be disrupted by xenobiotics.
  • Further research is needed to elucidate the precise mechanisms and consequences of xenobiotic interactions with myocardial signal transduction.

Related Concept Videos

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Pathophysiology of Cardiac Performance01:29

Pathophysiology of Cardiac Performance

Typical heart performance is influenced by heart rate, rhythm, myocardial contraction, and metabolism or blood flow. The cardiac muscle exhibits distinct electrophysiological features, including pacemaker activity and calcium channel control, which play a vital role in the heart's response to various drugs. The autonomic nervous system, comprising the sympathetic and parasympathetic branches, regulates heart rate. Sympathetic activation increases heart rate, while parasympathetic activation...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
Drug toxicity: Drug–Drug Interaction01:30

Drug toxicity: Drug–Drug Interaction

Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...